

106



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/993,966	11/27/2001	Michael Rohan	PP-016337.004	8065

45853 7590 01/13/2005

CHIRON CORPORATION
INTELLECTUAL PROPERTY - R440
PO BOX 8097
EMERYVILLE, CA 94662-8097

EXAMINER

YU, MISOOK

ART UNIT	PAPER NUMBER
----------	--------------

1642

DATE MAILED: 01/13/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/993,966

Applicant(s)

ROHAN ET AL.

Examiner

MISOOK YU, Ph.D.

Art Unit

1642

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 22 October 2004.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-38 is/are pending in the application.
- 4a) Of the above claim(s) 23-38 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-22 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date _____ | 6) <input checked="" type="checkbox"/> Other: <u>See Continuation Sheet</u> . |

Continuation of Attachment(s) 6). Other: Exhibit A (sequence alignment) .

DETAILED ACTION

Election/Restrictions

Applicant's election without traverse of group 1, claims 1-22 in the reply filed on 10/22/2004 is acknowledged.

Claims 23-38 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention.

Claims 1-38 are pending. Claims 1-22 are examined on merits.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 4, 9, and 13 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 4, and 9 are confusing as to the property boundary set by the limitation "the coding region of SEQ ID NO:5" because claim 9 recites "the 1416 nucleotides that constitute the coding region of SEQ ID NO:5", but this definition contradicts with the disclosure of specification at Fig. 1-1 to Fig. 1-3, where it discloses that the coding region starts with the codon ATG, and ends with TAG, which is a stop codon. The instant SEQ ID NO:5 encodes the human protein of SEQ ID NO:7, which is 470 amino acids in length. Based on the simple calculation of 470×3 (a codon for each of the 470 amino acids) + 3 (stop codon) = 1413, the 1413 nucleotides between ATG at nucleotide

Art Unit: 1642

224 to # 1636 of instant SEQ ID NO:5 should constitute the coding region of SEQ ID NO:5 according to specification at Fig. 1-1 to Fig. 1-3.

For the purpose of this Office action, the Office assumes that 1413 nucleotides constitute the coding region of SEQ ID NO:5. However, this treatment does not relieve applicant the burden of responding to this rejection.

The property boundary set by claim 13 as currently construed is vague and confusing because the limitations, i.e. "at least one conservative amino acid substitution" and "said polypeptide comprises an amino acid sequence selected from" the four choices listed as (a)-(d) contradict each other.

The specification at paragraph [0074] discloses "Percent conservation is calculated from the above alignment by adding the percentage of identical residues to the percentage of positions at which the two residues represent a conservative substitution (defined as having a log odds value of greater than or equal to 0.3 in the PAM250 residue weight table). Conservation is referenced to human Nkd when determining percent conservation with non-human Nkd, e.g. mNkd, when determining percent conservation. Conservative amino acid changes satisfying this requirement are: R-K; E-D, Y-F, L-M; V-I, Q-H." This disclosure indicates that "at least one conservative amino acid substitution" is within amino acids 2 to 460, or 1-460 of SEQ ID NO:7 since the limitation "substitution" requires a reference amino acid in this case, amino acids 2 to 460, or 1-460 of SEQ ID NO:7. However, the limitation "said polypeptide **comprises**" an amino acid sequence selected from one of the four Markush group members, which one of them is the polypeptide comprising the amino acids 2 to 460 of SEQ ID NO:7.

Art Unit: 1642

For purpose of this Office action, the scope of the claimed nucleic acid includes nucleic acid molecule encoding at least one amino acid substitution within the amino acids 2 to 460 of SEQ ID NO:7. However this treatment does not relieve applicant the burden of responding to this rejection.

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-3, 5-9, 10-22 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

The applicable standard for the written description requirement can be found: MPEP 2163; University of California v. Eli Lilly, 43 USPQ2d 1398 at 1407; PTO Written Description Guidelines; Enzo Biochem Inc. v. Gen-Prove Inc., 63 USPQ2d 1609; Vas-Cath Inc. v. Mahurkar, 19USPQ2d 1111; and University of Rochester v. G.D. Searle & Co., 69 USPQ2d 1886 (CA FC 2004).

To provide adequate written description and evidence of possession of a claimed genus, the specification must provide sufficient distinguishing identifying characteristics of the genus. The factors to be considered include disclosure of complete or partial structure, physical and/or chemical properties, functional characteristics,

structure/function correlation, methods of making the claimed product, or any combination thereof.

In this case, the only factor present in the claims is a partial structure of in the form of % identity or partial structure in form of a partial cDNA fragment with the open transitional phrase encoding a partial protein of a full-length protein. The present claims encompass full-length genes and cDNAs (such as differently spliced isoforms of said full-length gene) that are not further described. There is substantial variability among the species of DNA s encompassed within the scope of the claims because amino acids 1, or 2 to 460 of SEQ ID NO:7 is a fragment (a partial structure) of a full length protein encoded by a cDNA species. They are structurally unrelated. A description of a genus of cDNA may be achieved by means of a recitation of a representative number of cDNAs, defined by nucleotide sequences, falling within the scope of the genus or of a recitation of structural features common to the members of the genus, which features constitute a substantial portion of the genus.

The claimed partial structures are not associated with any other physical and/or chemical properties, functional characteristics. There is no sufficient distinguishing identifying characteristics of the genus. There is no structure/function correlation of the genus. Accordingly, in the absence of sufficient recitation of distinguishing identifying characteristics, the specification does not provide adequate written description of the claimed genus.

Claim 13 lacks written description because the polypeptides with at least one conservative amino acid substitution is not associated any other associated with any

other physical and/or chemical properties, functional characteristics. It is noted all of amino acids 2 to 460 or 1 to 460 could be changed to be within the boundary of set by instant claim 13. AS for the limitation in claim 13 (c) and (d), the specification does not teach how the structure of a non-human primate homologue of SEQ ID NO:7 looks like.

Claims 14-22 lacks written description for the same reason as the base claims they depend on.

Vas-Cath Inc. v. Mahurkar, 19USPQ2d 1111, clearly states “applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of the invention. The invention is, for purposes of the ‘written description’ inquiry, *whatever is now claimed*.” (See page 1117.) The specification does not “clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is claimed.” (See Vas-Cath at page 1116). As discussed above, the skilled artisan cannot envision the detailed chemical structure of the encompassed genus of nucleic acid molecules, given that the specification has only described SEQ ID NO: 5 and 1. Therefore, only isolated nucleic acid comprising SEQ ID NO:1 and 5, but not the full breadth of the claim meets the written description provision of 35 U.S.C. §112, first paragraph.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

Art Unit: 1642

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Claims 1, 5-8, and 10-22 are rejected under 35 U.S.C. 102(e) as being anticipated by US Pat. 6,630,323 (effective filing date: Feb. 17, 1999, filing date: February 17, 2000, issue date: Oct. 7, 2003).

Claims 1, 5-8, and 10-22 are interpreted as drawn to an isolated nucleic acid comprising a polynucleotide that is at least 90% identical to a polynucleotide encoding a polypeptide comprising amino acids 1 to 460 of SEQ ID NO:7 (claim 1), or at least one amino conservative amino acid substitution in said polypeptide (claim 13), comprising at least **50** (claim 5), **200** (claim 6), **500** (claim 7), or **750** (claim 8) contiguous nucleotides of the coding region of SEQ ID NO:5, at least 90% (claim 10), or 95% (claims 11, and 12) identical to the coding region of SEQ ID NO:5, wherein a recombinant vector comprising said nucleic acid operatively linked to a promoter is claimed in claims 14-16, and a host comprising said recombinant vector is claimed in claims 17-19, and a method of producing a polypeptide using said host cell is claimed in claims 20-22.

US Pat. 6,630,323 teaches an isolated nucleic acid, i.e. SEQ ID NO:5 comprising a polynucleotide that is at least 90% identical to a polynucleotide encoding a polypeptide comprising amino acids 1 to 460 of SEQ ID NO:1, or at least one amino conservative amino acid substitution in said polypeptide, comprising at least **50**, **200**, **500** or **750** contiguous nucleotides of the coding region of SEQ ID NO:5, at least 90%, or 95% identical to the coding region of SEQ ID NO:5. Note the attached Exhibit A

(sequence alignment) that the coding region of SEQ ID NO:5 is 99.8% identical to the coding region of instant SEQ ID NO:5. There is only one amino acid difference between the instant SEQ ID NO:7 and the protein encoded by SEQ ID NO:5 of US Pat.

6,630,323, i.e. Ser to Phe change at amino acid 290 of the instant SEQ ID NO:7. Since the specification does not define which amino acid is the conservative substitution of Ser, the Office broadly interprets that Phe is a conservative substitution since both are neural amino acids.

US Pat. 6,630,323 teaches a recombinant vector comprising nucleic acid encoding NKD polypeptide which is encoded by SEQ ID NO:5, wherein in said nucleic acid is operatively linked to a promoter, and a host comprising said recombinant vector, a method of producing said polypeptide using said host cell. Note column 6, line 22 to column 7, line 24.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to MISOOK YU, Ph.D. whose telephone number is 571-272-0839. The examiner can normally be reached on 8 A.M. to 5:30 P.M., every other Friday off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jeffrey C Siew can be reached on 571-272-0787. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Art Unit: 1642

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

MISOOK YU, Ph.D.
Examiner
Art Unit 1642

A handwritten signature in black ink, appearing to read 'Misook Yu', with a stylized flourish at the end.

**MISOOK YU
PATENT EXAMINER**

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - nucleic search, using frame_plus_p2n model

Run on: December 30, 2004, 03:23:44 ; Search time 141 Seconds
(without alignments)
2369.296 Million cell updates/sec

Title: US-09-993-966-7
Perfect score: 2499
Sequence: 1 MGKLSKPAACVCKRRSPG.....RHEHHHHHHHHHHYHFFYQT 470

Scoring table: BLOSUM62
Xgapop 10.0 , Xgapext 0.5
Ygapop 10.0 , Ygapext 0.5
Fgapop 6.0 , Fgapext 7.0
Delop 6.0 , Delext 7.0

Searched: 824507 seqs, 355394441 residues

Total number of hits satisfying chosen parameters: 1649014

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Command line parameters:

-MODEL=frame+ p2n.model -DEV=xlp
-Q=/cgn2_1/USPro_spool_p/US0993966/runat_29122004_130759_9030/app_query.fasta_1.647
-DB=issued Patents NA -QFMT=fastap -SUFFIX=rni -MINMATCH=0.1 -LOOPCL=0
-LOOPEXT=0 -UNITS=bits -START=1 -END=1 -MATRIX=blosum62 -TRANS=human40.cdi
-LIST=45 -DOCLINE=200 -NORM=ext -THR MAX=100 -THR MIN=0 -ALIGN=15
-MODE=LOCAL -OUTFMT=plo -NORM=ext -HEAPSIZ=500 -MINLEN=0 -MAXLEN=2000000000
-USPR=US0993966 @CGN 1 1 128 @runat_29122004_130759_9030 -NCPU=6 -ICPU=3
-NO_WMAP -LARGEQUERY -NEG_SCORES=0 -WAIT -DSPBLOCK=100 -LONGLOG
-DEV_TIMEOUT=120 -WARN_TIMEOUT=30 -THREADS=1 -XGAPOP=10 -XGAPEXT=0.5 -FGAPOP=6
-FGAPEXT=7 -YGAPOP=10 -YGAPEXT=0.5 -DELOP=6 -DELEXT=7

Database : Issued Patents NA.*
1: /cgn2_6/ptodata/1/ina/5A COMB.seq.*
2: /cgn2_6/ptodata/1/ina/5B COMB.seq.*
3: /cgn2_6/ptodata/1/ina/6A COMB.seq.*
4: /cgn2_6/ptodata/1/ina/6B COMB.seq.*
5: /cgn2_6/ptodata/1/ina/PCTUS COMB.seq.*
6: /cgn2_6/ptodata/1/ina/backfiles1.seq.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	2493	99.8	1438	4	US-09-506-066E-5
2	2174.5	87.0	1731	4	US-09-506-066E-3
3	783	31.3	1285	4	US-09-506-066E-7
4	583.5	23.3	1307	4	US-09-506-066E-9
5	215.5	8.6	4954	4	US-09-506-066E-1
6	160.5	6.4	2063	4	US-09-270-767-14537
7	153	6.1	1494	4	US-09-252-991A-15134
8	153	6.1	2226	4	US-09-252-991A-14877
9	153	6.1	2268	4	US-09-252-991A-14877
10	152	6.1	2433	4	US-08-999-689A-2
11	152	6.1	2433	4	US-09-944-807-3
12	149.5	6.0	4403765	3	US-09-103-840A-2

13	149.5	6.0	4411529	3	US-09-103-840A-1
14	146.5	5.9	2576	1	US-08-471-033-35
15	146.5	5.9	2576	2	US-08-471-044-35
16	146.5	5.9	2576	2	US-08-463-483A-35
17	146.5	5.9	2576	2	US-08-471-046A-35
18	146.5	5.9	2576	2	US-08-470-566B-35
19	146.5	5.9	2576	2	US-08-469-334-35
20	146.5	5.9	2576	3	US-09-300-529-35
21	146.5	5.9	2655	1	US-08-471-033-35
22	146.5	5.9	2655	1	US-08-471-033-26
23	146.5	5.9	2655	2	US-08-471-044-17
24	146.5	5.9	2655	2	US-08-471-044-26
25	146.5	5.9	2655	2	US-08-463-483A-17
26	146.5	5.9	2655	2	US-08-463-483A-26
27	146.5	5.9	2655	2	US-08-471-046A-17
28	146.5	5.9	2655	2	US-08-471-046A-26
29	146.5	5.9	2655	2	US-08-470-566B-17
30	146.5	5.9	2655	2	US-08-470-566B-26
31	146.5	5.9	2655	2	US-08-469-334-17
32	146.5	5.9	2655	2	US-08-469-334-26
33	146.5	5.9	2655	3	US-09-300-529-17
34	146.5	5.9	2655	3	US-09-300-529-26
35	146.5	5.9	4031	1	US-08-471-033-49
36	146.5	5.9	4031	2	US-08-471-044-49
37	146.5	5.9	4031	2	US-08-463-483A-49
38	146.5	5.9	4031	2	US-08-471-046A-49
39	146.5	5.9	4031	2	US-08-470-566B-49
40	146.5	5.9	4031	2	US-08-469-334-49
41	146.5	5.9	4031	3	US-09-300-529-49
42	146	5.8	5194	1	US-09-599-652-1
43	146	5.8	5194	2	US-08-642-846-1
44	146	5.8	5194	2	US-09-264-604-1
45	146	5.8	5194	4	US-10-002-389-1

ALIGNMENTS

RESULT 1

US-09-506-066E-5

; Sequence 5, Application US/09506066E

; Patent No. 6630323

; GENERAL INFORMATION:

; APPLICANT: Scott, Matthew

; APPLICANT: Wharton, Keith

; APPLICANT: Zeng, Wenlin

; TITLE OF INVENTION: Naked Cuticle Genes and their Uses

; FILE REFERENCE: STAN-121

; CURRENT APPLICATION NUMBER: US/09/506,066E

; CURRENT FILING DATE: 2000-02-17

; PRIOR APPLICATION NUMBER: 60/120,646

; PRIOR FILING DATE: 1999-02-17

; NUMBER OF SEQ ID NOS: 15

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 5

; TYPE: DNA

; ORGANISM: Homo sapiens

; FEATURE:

; NAME/KEY: CDS

; LOCATION: (8)...(1418)

; OTHER INFORMATION: Nkdl coding sequence

US-09-506-066E-5

Alignment Scores:

Pred. No.: 8.39e-206

Score: 2493.00

Length: 1438

Matches: 469

Percent Similarity: 99.79%

Conservative: 0

Best Local Similarity: 99.79%

Mismatches: 1

Indels: 0

Query Match: 99.76%

Gaps: 0

DB:

US-09-993-966-7 (1-470) x US-09-506-066E-5 (1-1438)

Exhibit A

182

QY 1 MetGlyLysLeuHisSerLysProAlaAlaValCysLysArgArgGluSerProGluGly 20
DB 8 ATGGAGAACTTCACTCCAAAGCCGCGCGTGTGCAAGCGAGGAGAGCCCGAAGGT 67
QY 41 AspSerPheAlaValSerAlaAlaTrpAlaArgLysGlyIleGluGluTrpIleGlyArg 40
DB 68 GACAGCTTCGCGCTGAGCGTGTCTGGCTGCGAAGGCGCATCGAGGAGTGGATCGGGAGA 127
QY 41 GlnArgCysProGlyGlyValSerGlyProArgGlnLeuArgLeuAlaGlyThrIleGly 60
DB 128 CAGCGTGTCCGCGCGTGTCTCGGACCCGACAGCTGCGGTGGCGGCGCATAGGC 187
QY 61 ArgSerThrArgGluLeuValGlyAspValLysuArgAspThrLeuSerGluGluGlu 80
DB 188 CGAAGCACCCGCGAGCTCGTGGCGCGAGTGTGAGAGACACGCTCAGCGAGGAGGAG 247
QY 81 AspAspPheArgLeuGluValAlaLeuProGluLysuArgAspThrLeuSerGly 100
DB 248 GACGACTTTCGCTGGAAGTGGCCCTGCTCTGAGAGACATGACGGGTGGCGAGCGGA 307
QY 101 AspGluLysLysMetGluArgValSerGluProCysProGlySerLysLysGlnLeuLys 120
DB 308 GATGAGAGAGATGAGAGATGAGCGAAGCTGCCCCAGGCTCCAGAGGAGCTGAG 367
QY 121 PheGluGluLeuGlnCysAspValSerMetGluGluAspSerArgGlnGluTrpThrPhe 140
DB 368 TTTGAGAGCTTCAGTGGACGTGTCTGATGGAGGAGCAGCGCGAGGTGAGCTTC 427
QY 141 ThrLeuTyrAspPheAspAsnAsnGlyLysValThrArgGluAspIleThrSerLeuLeu 160
DB 428 ACCCTGTATGACTTTGACACACCGCAGGTCAACCGAGGAGCATCACGAGCTTGTG 487
QY 161 HisThrIleTyrGluValValAspSerSerValAsnHisSerProThrSerSerLysMet 180
DB 488 CACACCATCTATAGGTGGTGTGCTCTGTCAACCACTCCCAACATCCAGCAGATG 547
QY 181 LeuArgValLysLeuThrValAlaProAspGlySerGlnSerLysArgSerValLeuVal 200
DB 548 CTGGCGTAAAGCTTCACTGCGTGGCGCGCATGGCAGCCAGAGAGAGCGTCTGTGTC 607
QY 201 AsnGlnAlaAspLeuGlnSerAlaArgProArgAlaGluThrLysProThrGluAspLeu 220
DB 608 AATCAGGCTGACCTTGCAGAGCGCAGCGCCCGACAGACAGCAAGCCCATCGAGGACCTG 667
QY 221 ArgSerTrpGluLysLysGlnArgAlaProLeuArgPheGlnGlyAspSerArgLeuGlu 240
DB 668 CGGAGCTGGGAGAGAGAGCAGCGAGCGCGCTCAGGTTCAGGTTGACAGCGCGCTGGAG 727
QY 241 GlnSerGlyCysTyrHisHisCysValAspGluAsnIleGluArgArgAsnHisTyrLeu 260
DB 728 CAGTCTGGCTGTACCACTTGGTGTAGTGAACATCGAGAGGAGAGAAACCACTACTTA 787
QY 261 AspLeuAlaGlyIleGluAsnTyrThrSerGlnPheGlyProGlySerProSerValAla 280
DB 788 GATCTCGCGGATAGAAACTACAGTCCCAATTTGGCGTGTGCTCCCTCCCTCGTGGCC 847
QY 281 GlnLysSerGluLeuProArgThrSerAspProThrArgSerArgSerHisGluPro 300
DB 848 CAGAGTCAGAACTGCCCCCGCCCTCAATCCCACTCCGATCTCGCTCCCATGAGCGG 907
QY 301 GluAlaIleHisIleProHisArgLysProGlnGlyValAspProAlaSerPheHisPhe 320
DB 908 GAAGCCATCCACATCCACACCCAGGAGCCCAAGGCGTGGACCCGCGCTCCCTCCACTTC 967
QY 321 LeuAspThrProIleAlaLysValSerGluLeuGlnArgLeuArgGlyThrGlnAsp 340
DB 968 CTTGACACCCCAATCGCCAAAGTCTCAGAGCTCCAGCAACCGCTCCGCGGCACTCAGGAC 1027
QY 341 GlySerLysHisPheValArgSerProLysAlaGlnGlyLysSerValGlyValGlyHis 360
DB 1028 GCGAGCAAGCACTTGTGAGGTCCCCCAAGGCCAGGAGTGTGGTGTGGGCCAC 1087
QY 361 ValAlaArgGlyAlaArgAsnLysProProLeuGlyProAlaIleProAlaValSerPro 380

DB 1088 GTGGCAGAGGGGCAAGAAACCAAGCCCTCTGGACCCGCGCATCTCTGGGTGTCCCC 1147
QY 381 SerAlaHisLeuAlaAlaSerProAlaLeuLeuProSerLeuAlaProLeuGlyHisLys 400
DB 1148 TCGCCCACTGGCTGCCAGCCGCGCTCTCTCCCTCTAGCCCTCTCGGGCACAAG 1207
QY 401 LysHisLysHisArgAlaLysGluSerGlnGlnGlyCysArgGlyLeuGlnAlaProLeu 420
DB 1208 AAGCAACAGCACCGAGCAGGAGGAGGAGGAGGCTGCCGGGCTTCAGGACCACTG 1267
QY 421 AlaSerGlyGlyProValLeuGlyArgGluHisLeuArgGluLeuProAlaLeuVal 440
DB 1268 GCTTCAGGTGGCCCTGTCTCTGGGGGGGAGCACTCTCGGAGCTGCCCTTGTGTG 1327
QY 441 TyrGluSerGlnAlaGlyGlnProValGlnArgHisGluHisHisHisGluHis 460
DB 1328 TATGAGAGCAGGCTCGGCGAGCGCTCTCAGAGCATGATGACCAACCACTATGACAT 1387
QY 461 HisHisHisTyrHisHisPheTyrGlnThr 470
DB 1388 CACCACCATTACCACCACTTCTACCAACA 1417

US-09-506-066E-3
; Sequence 3, Application US/09506066E
; Patent No. 6630323

; GENERAL INFORMATION:
; APPLICANT: Scott, Matthew
; APPLICANT: Wharton, Keith
; APPLICANT: Zeng, Wenlin
; TITLE OF INVENTION: Naked Cuticle Genes and their Uses
; FILE REFERENCE: STAN-121
; CURRENT APPLICATION NUMBER: US/09/506,066E
; PRIOR FILING DATE: 2000-02-17
; PRIOR APPLICATION NUMBER: 60/120,646
; PRIOR FILING DATE: 1999-02-17
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 1731
; TYPE: DNA
; ORGANISM: Mus musculus
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (140)...(1553)
; OTHER INFORMATION: Nkdl coding sequence

US-09-506-066E-3
Alignment Scores:
Pred. No.: 3,46E-178 Length: 1731
Score: 2174.50 Matches: 407
Percent Similarity: 90.64% Conservative: 19
Best Local Similarity: 86.60% Mismatches: 43
Query Match: 87.01% Indels: 1
DB: 4 Gaps: 1

US-09-993-966-7 (1-470) x US-09-506-066E-3 (1-1731)
QY 1 MetGlyLysLeuHisSerLysProAlaAlaValCysLysArgArgGluSerProGluGly 20
DB 140 ATGGGAAACTTCACTCGAAGCCGCGCGTGTGCAAGCGAGGAGGAGCGGAGAGGT 199
QY 21 AspSerPheAlaValSerAlaAlaTrpAlaArgLysGlyIleGluGluTrpIleGlyArg 40
DB 200 GACAGCTTGTGTAAAGCGCTGTGGCGAGGAGGAGGAGGATCGAGGAGTGGATCGGAGG 259
QY 41 GlnArgCysProGlyGlyValSerGlyProArgGlnLeuArgLeuAlaGlyThrIleGly 60
DB 260 CAGCGCTCTCGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 319
QY 61 ArgSerThrArgGluLeuValGlyAspValLeuArgAspThrLeuSerGluGluGlu 80